SCD and non-small cell lung carcinoma: Additionally, the key enzyme SCD1 and the LD-surrounding proteins perilipins are upregulated after Gefitinib treatment in NSCLC, indicating that abnormal lipid metabolism may be responsible for Gefitinib resistance.